Abstract
Previous studies have found reduced concentrations of both leptin and resistin after glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment; however, the evidence in this field is inconclusive. Therefore, the aim of this meta-analysis of randomized controlled trials was to evaluate the effect of GLP-1 RA on both leptin and resistin levels. The present systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on leptin and resistin concentrations. For this, PubMed-MEDLINE, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched. A random-effects model and a sensitivity analysis were performed for meta-analysis. Meta-analysis of 13 randomized controlled trials comprising 1,025 subjects indicated that administration of GLP-1 RA significantly decreases leptin (WMD: -4.85 ng/mL, 95% CI: -9.32, -0.38, p = 0.03) and resistin (WMD: -1.40 ng/mL, 95% CI: -2.78, -0.01, p = 0.05) serum levels. However, the effect size was sensitive to four studies for both leptin and resistin concentrations. The results of this meta-analysis of randomized controlled trials suggest that GLP-1 RA therapy reduces both leptin and resistin levels.
References
Feb 24, 2001·Nature·C M SteppanM A Lazar
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Peter F BodaryDaniel T Eitzman
Apr 6, 2002·Archives of Physiology and Biochemistry·G N ChaldakovL Aloe
Oct 9, 2002·Circulation·John P Cooke, Roberta K Oka
Aug 15, 2003·The Journal of Biological Chemistry·Thomas LundåsenMats Rudling
Apr 21, 2005·BMC Medical Research Methodology·Stela Pudar HozoIztok Hozo
Dec 26, 2006·Regulatory Peptides·Daniel E FlanaganJeffrey S Robinson
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Feb 16, 2010·Diabetes Technology & Therapeutics·G DerosaA F G Cicero
Apr 29, 2010·Diabetes Care·Mathijs C BunckUlf Smith
May 7, 2011·British Journal of Pharmacology·Md S JamaluddinChangyi Chen
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Jan 13, 2012·BMJ : British Medical Journal·Tina VilsbøllLise Lotte Gluud
Jun 23, 2012·Diabetologia·Y-S LeeH-S Jun
Jun 8, 2013·Pharmacotherapy·Giuseppe DerosaPamela Maffioli
Oct 8, 2014·International Journal of Obesity : Journal of the International Association for the Study of Obesity·E W IepsenS S Torekov
Dec 3, 2014·Diabetes Research and Clinical Practice·Eren GurkanZeynep Canturk
Dec 20, 2014·BMC Medical Research Methodology·Xiang WanTiejun Tong
Mar 25, 2015·Journal of Diabetes Investigation·Yumie TakeshitaUNKNOWN Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group
Sep 4, 2015·American Journal of Physiology. Endocrinology and Metabolism·Amaia RodriguezGema Frühbeck
Sep 17, 2015·Diabetes Research and Clinical Practice·Dongmei LiJianhua Ma
Sep 24, 2015·Journal of Hepatology·Matthew J ArmstrongJeremy W Tomlinson
Jun 11, 2016·Metabolism: Clinical and Experimental·Olivia M FarrChristos S Mantzoros
Feb 6, 2017·Obesity Research & Clinical Practice·Li ShiXinhua Ye
Jul 7, 2017·Diabetes, Obesity & Metabolism·Signe FrøssingJens Faber
Sep 16, 2017·Experimental and Therapeutic Medicine·Huibiao QuanKaining Chen
Jul 12, 2018·European Journal of Clinical Investigation·Xabier UnamunoVictoria Catalán
Oct 6, 2018·Nature Reviews. Cardiology·Evangelos K Oikonomou, Charalambos Antoniades
Nov 22, 2018·Frontiers in Pharmacology·Yaojing JiangRui Liu
Nov 7, 2019·Nutrients·Manuel F LandechoGema Frühbeck
May 20, 2020·Diabetes, Obesity & Metabolism·Husam GhanimParesh Dandona